We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+2.6%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.34B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
4.72%
Top 10 Hldgs %
12.01%
Holding
1,564
New
189
Increased
576
Reduced
529
Closed
163

Sector Composition

Rank Sector Weight
1 Energy 11.94%
2 Healthcare 10.62%
3 Industrials 9.8%
4 Technology 9.43%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INCY icon
501
Incyte
INCY
$24.2B
$1.33M 0.04%
24,865
+19,780
+389% +$1.23M
SCG
502
DELISTED
Scana
SCG
$1.33M 0.04%
25,867
-1,366
-5% -$65.7K
FEP icon
503
First Trust Europe AlphaDEX Fund
FEP
$524M
$1.32M 0.04%
+36,814
New +$1.27M
ETP
504
DELISTED
Energy Transfer Partners, L.P.
ETP
$1.32M 0.04%
28,978
-5,508
-16% -$220K
ETG
505
Eaton Vance Tax-Advantaged Global Dividend Income Fund
ETG
$1.8B
$1.31M 0.04%
77,944
+66,218
+565% +$1.11M
RQI icon
506
Cohen & Steers Quality Income Realty Fund
RQI
$1.7B
$1.31M 0.04%
124,112
+14,980
+14% +$151K
ULTA icon
507
Ulta Beauty
ULTA
$21.8B
$1.3M 0.04%
+13,362
New +$1.2M
CBRE icon
508
CBRE Group
CBRE
$42.6B
$1.3M 0.04%
47,303
-2,919
-6% -$78.7K
SDRL
509
DELISTED
Seadrill Limited Common Stock
SDRL
$1.29M 0.04%
138
+70
+103% +$688K
LEG icon
510
Leggett & Platt
LEG
$1.36B
$1.29M 0.04%
39,493
+4
+0% +$124
DRE
511
DELISTED
Duke Realty Corp.
DRE
$1.29M 0.04%
76,375
+16,250
+27% +$259K
DBD
512
DELISTED
Diebold Nixdorf Incorporated
DBD
$1.29M 0.04%
32,261
+26,121
+425% +$940K
PCYC
513
DELISTED
PHARMACYCLICS INC
PCYC
$1.28M 0.04%
12,752
+1,562
+14% +$203K
WST icon
514
West Pharmaceutical
WST
$23.9B
$1.28M 0.04%
29,000
-72
-0.2% -$3.39K
WELL icon
515
Welltower
WELL
$170B
$1.27M 0.04%
21,384
+14,330
+203% +$819K
HLT icon
516
Hilton Worldwide
HLT
$71.8B
$1.27M 0.04%
+19,100
New +$1.26M
IOO icon
517
iShares Global 100 ETF
IOO
$8.85B
$1.27M 0.04%
32,622
+186
+0.6% +$7.06K
WEN icon
518
Wendy's
WEN
$1.4B
$1.26M 0.04%
138,681
+9,605
+7% +$88K
BNY
519
Bank of New York Mellon
BNY
$106B
$1.26M 0.04%
35,798
+751
+2% +$24.8K
SJNK icon
520
State Street SPDR Bloomberg Short Term High Yield Bond ETF
SJNK
$4.88B
$1.25M 0.04%
40,441
+2,168
+6% +$67K
JAH
521
DELISTED
JARDEN CORPORATION
JAH
$1.25M 0.04%
31,376
-39,661
-56% -$1.61M
WYNN icon
522
Wynn Resorts
WYNN
$10.2B
$1.25M 0.04%
5,627
-1,515
-21% -$333K
LEN icon
523
Lennar Class A
LEN
$19.9B
$1.25M 0.04%
33,093
-46
-0.1% -$1.76K
EBAY icon
524
eBay
EBAY
$50.2B
$1.25M 0.04%
53,650
-69,603
-56% -$1.62M
FLR icon
525
Fluor
FLR
$7B
$1.25M 0.04%
16,041
-625
-4% -$48.7K

Similar funds

Oppenheimer & Co's Q1 2014 Portfolio in Review

As of Q1 2014, Oppenheimer & Co held 1,564 positions worth $3.34B, up 6.7% from $3.13B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Oppenheimer & Co deployed $157M of net new capital in Q1 2014, opening 189 new positions and adding to 576 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.

By sector, the portfolio is most concentrated in Energy at 12% of assets, down from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Vanguard Dividend Appreciation ETF, an estimated $7.79M trimmed.

  • Oppenheimer & Co's largest Q1 2014 buy was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.
  • Oppenheimer & Co added most to Monsanto Co in Q1 2014, an estimated $30M increase.
  • Oppenheimer & Co's biggest Q1 2014 reduction was Vanguard Dividend Appreciation ETF, cutting an estimated $7.79M.
  • Oppenheimer & Co fully exited TetraLogic Pharmaceuticals Corporation in Q1 2014, selling an estimated $10.2M.
  • Oppenheimer & Co's ten largest holdings make up 12% of its $3.34B portfolio in Q1 2014.
  • Oppenheimer & Co opened 189 new positions and closed 163 in Q1 2014.
  • Oppenheimer & Co's portfolio value rose 6.7% quarter-over-quarter to $3.34B.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.